Your browser doesn't support javascript.
loading
Rituximab-bortezomib-dexamethasone induce high response rates in iMCD in clinical practice.
Yin, Xuejiao; Liu, Yi; Zhong, Chengli; Lv, Yunfei; Xu, Dan; Zhu, Li; Jin, Jie; Meng, Haitao; You, Liangshun.
Afiliación
  • Yin X; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
  • Liu Y; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, People's Republic of China.
  • Zhong C; Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou, People's Republic of China.
  • Lv Y; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
  • Xu D; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, People's Republic of China.
  • Zhu L; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
  • Jin J; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, People's Republic of China.
  • Meng H; Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People's Republic of China.
  • You L; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, People's Republic of China.
Br J Haematol ; 203(5): 803-806, 2023 12.
Article en En | MEDLINE | ID: mdl-37485679
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Castleman Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Br J Haematol Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad de Castleman Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Br J Haematol Año: 2023 Tipo del documento: Article